It was reported yesterday that the FDA's Division of Neurology Products has granted request for Fast Track Designation for United States-based Sound Pharmaceuticals' SPI-1005 intended for the treatment of Meniere's Disease.
The company's clinical data from two completed multi-centre, randomised, placebo-controlled studies indicated that 21 or 28 days of oral treatment improved tinnitus and restored sensorineural hearing loss in patients affected by Meniere's Disease.
Fast Track Designation enables the accelerated development of SPI-1005 involving more frequent meetings with the FDA, rolling reviews, and the potential for priority review at the filing of New Drug Application. SPI has an End-of-Phase 2 Meeting scheduled with the FDA to discuss its Phase 3 study design and additional data required for NDA filing.
Jonathan Kil, MD, Co-Founder and CEO, said, 'This is a major regulatory milestone for our most advanced clinical program to date.'
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio